Drug profile · INN
erythromycin
MAYNE PHARMA ERYTHROMYCIN
erythromycin (MAYNE PHARMA ERYTHROMYCIN) is a bacterial 70s ribosome inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — erythromycin
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 20
- Programs
- 25
- Data quality
- 0.89
Quick answer
erythromycin (MAYNE PHARMA ERYTHROMYCIN) is a bacterial 70s ribosome inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2025172818
POLYTHÉRAPIE À BASE DE PYRILUTAMIDE
granted -
US 12370255
Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
granted -
US 12365659
Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers
granted -
US 12343424
Photochemically stable, non-leaching, bridged polysilsesquioxane based sunscreens
granted -
US 12311054
Compositions and methods of using propylene sulfide-based polymers for treatment of Chagas disease
granted -
US 12281056
Methods for making and using endoxifen
granted -
US 12275684
Methods for making and using endoxifen
granted -
US 12264366
Genome-based methods for reducing cardiovascular risk
granted -
US 12233103
Indoleamine 2,3-dioxygenase based immunotherapy
granted -
US 12201591
Sustained release compositions of endoxifen
granted -
US 12144877
Graphene-based multifunctional cosmetic compositions
granted -
US 12133884
Methods of substituting pathogenic amino acids using programmable base editor systems
granted -
US 12076443
Preparation method of nanozyme composite-based hybrid hydrogel eye drop
granted -
US 12071391
Methods for making and using endoxifen
granted -
US 12029755
Carbon monoxide-based therapies and implantable devices for the treatment of vascular disease
granted -
US 11993603
Preparation for 6-amino-1H-pyrazolo[3,4-d]pyrimidine-based JAK kinase inhibitor and application thereof
granted -
US 11964960
Pyridinone- and pyridazinone-based compounds and uses thereof
granted -
US 11904006
Poly(diaminosulfide) particle-based vaccine
granted -
US 11890306
Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
granted -
WO 2024023766
POLYTHÉRAPIE À BASE D'INHIBITEUR DE P13K
granted
Frequently asked questions
What is erythromycin?
erythromycin (MAYNE PHARMA ERYTHROMYCIN) is a bacterial 70s ribosome inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for erythromycin?
MAYNE PHARMA ERYTHROMYCIN is a marketed brand name for erythromycin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of erythromycin?
erythromycin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.